药物查揭示了针对Mpox病毒的新型强效宿主向抗病毒药物
Research square
|June 12, 2025
概括
新的宿主定向激酶抑制剂对Mpox病毒 (MPXV) 有希望. 研究人员选了2,750种化合物,确定了几种有效的抗病毒药物,这些药物减少了小鼠的MPXV复制和皮肤病变,为新的治疗提供了希望.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 传染性疾病 传染性疾病
背景情况:
- 马普克斯病毒 (MPXV) 是一种重新出现的动物性传染病原体,导致全球爆发.
- 目前的治疗方法,如tecovirimat (TPOXX),有效性有限,需要开发新的抗病毒药物.
- MPXV Clade IIb和Clade Ib爆发突显了迫切需要有效的MPXV治疗方法.
研究的目的:
- 使用主导激酶抑制剂库识别针对MPXV的新型抗病毒化合物.
- 评估已识别的化合物在减少MPXV复制和细胞病变影响方面的疗效.
- 在MPXV感染的临床前模型中评估化合物的治疗潜力.
主要方法:
- 对2,750种宿主导激酶抑制剂进行针对MPXV (Clade IIb) 的高通量选.
- 二级和三级选用于识别强效,无毒的抗病毒化合物.
- 在人体表皮层原发性角质细胞中的体外验证和MPXV皮肤感染的小鼠模型中的体内测试.
主要成果:
- 138种化合物抑制了MPXV的细胞病变效应,包括EGFR,PI3K-mTOR,Ras/Raf的抑制剂和亡/自的调节剂.
- 三种化合物 (IRAK4-IN-6,SM-7368,KRAS抑制剂-10) 减少了MPXV诱导的细胞死亡.
- 伊拉克4-IN-6和SM-7368调节了NF-κB和STING信号传递,并减少了小鼠的皮肤病变和病毒负担.
结论:
- 这项研究确定了针对MPXV的新型宿主导抗病毒化合物的新类.
- 作为MPXV治疗药物,IRAK4-IN-6和SM-7368显示出临床开发的巨大潜力.
- 这些发现为打击MPXV疫情和公共卫生紧急情况提供了有希望的候选人.
相关概念视频
Subviral Agents
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


